CHINARES PHARMA (03320.HK) announced that the new indication application for recombinant human tissue-type plasminogen activator injection (Ruitongli) submitted by its subsidiary, CHINARES PHARMA Biopharmaceutical Co., Ltd., has been approved for thrombolytic treatment in patients with acute ischemic stroke (AIS).

As a third-generation intravenous thrombolytic drug, Ruitongli only includes the natural tissue-type plasminogen activator's high specificity for fibrin and the enzymatic activity region, providing a longer half-life and a stronger thrombolytic effect. Stroke is one of the leading causes of death in China and globally, characterized by high mortality and high disability rates. Approximately 2 million new cases of stroke occur in China each year, with ischemic stroke accounting for about 80%, and intravenous thrombolysis is currently the primary treatment for ischemic stroke.